Halt Medical, Inc. Receives FDA Clearance
LIVERMORE, Calif., June 15 /PRNewswire/ -- Halt Medical, Inc., today announced that the U.S. Food and Drug Administration (FDA) has cleared the Halt 2000GIâ„¢ Electrosurgical System for soft tissue ablation using radiofrequency energy.  "This clearance to market is a major milestone for our customers, employees and investors," said Russ DeLonzor, President and Chief Operating Officer.  Radiofrequency Ablation (RFA) with the Halt System is a very precise, minimally invasive procedure where a slender probe is inserted into the target tumor under ultrasound guidance.  Once in position, the system delivers a specified amount of energy to the tissue.  The heat generated in the process destroys the tumor, allowing it to be absorbed by the body.

PregLem Announces Positive Phase III Results for Esmya(TM)
GENEVA, Switzerland, June 3, 2010 /PRNewswire/ -- - PEARL I Trial Meets Primary Efficacy and Safety Endpoints - PregLem Preparing for Submission to the European Medicines Agency in 2010 PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide. The final set of positive Phase III results, combined with the positive PEARL II results announced in May 2010, will enable PregLem to submit a Marketing Authorisation Application (MAA) to the Eu...

IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
EDMONTON, May 11 /PRNewswire/ - IMBiotechnologies Ltd. ("IMBio"), a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration (FDA) to market its lead product, Occlusin(R) 500 Artificial Embolization Device (OCL 500) in the U.S.

Fibroid Growth and Its Relation to Estrogen Dominance
Estrogen is said to stimulate cellular tissue growth especially in the estrogen sensitive female reproductive organs The hormone progesterone makes tissue more fertile and helps to control duration and intensity of estrogenic effect